drugset / Trial / NCT00545025

Revaccination With Influenza Vaccine GSK1247446A

NCT00545025 ↗

Phase 2 Completed 243 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.

Timeline

Start
2007-10-15
Primary completion
2007-12-12
Completion
2007-12-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluarix Vaccine — Intramuscular
Subject GSK1247446A Vaccine — Intramuscular

Indications